Preservation of gonadal function in women undergoing chemotherapy: a systematic review and meta-analysis of the potential role for gonadotropin-releasing hormone agonists

Journal of Assisted Reproduction and Genetics

Volumn 35, Issue 4, 2018, Pages 571-581

  Hickman, Lisa C ^a   Llarena, Natalia C ^a   Valentine, Lindsey N ^a   Liu, Xiaobo ^a   Falcone, Tommaso ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Chemotherapy; Gonadotropin releasing hormone; Ovarian function; Premature ovarian failure; Systematic review

Indexed keywords

ANTINEOPLASTIC AGENT; ESTRADIOL; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN; LHRH, ALA(6)-GLY(10)-ETHYLAMIDE-;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; DRUG SAFETY; GONAD FUNCTION; HUMAN; LYMPHOMA; META ANALYSIS; OUTCOME ASSESSMENT; OVARIAN PRESERVATION; OVARY CANCER; OVARY FUNCTION; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; AGONISTS; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; DRUG EFFECT; FEMALE; GONAD; META ANALYSIS (TOPIC); NEOPLASM; PHYSIOLOGY; PREGNANCY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; FEMALE; GONADOTROPIN-RELEASING HORMONE; GONADS; HUMANS; META-ANALYSIS AS TOPIC; NEOPLASMS; PREGNANCY; PRIMARY OVARIAN INSUFFICIENCY; TREATMENT OUTCOME;

EID: 85042375401     PISSN: 10580468     EISSN: 15737330     Source Type: Journal    
DOI: 10.1007/s10815-018-1128-2     Document Type: Review

References (51)

1. Levine JM, Kelvin JF, Quinn GP, Gracia CR. Infertility in reproductive-age female cancer survivors. Cancer. 2015;121:1532–9. 10.1002/cncr.29181.
2. Trivers KF, Fink AK, Partridge AH, Oktay K, Ginsburg ES, Li C, et al. Estimates of young breast cancer survivors at risk for infertility in the U.S. Oncologist. 2014;19:814–22. 10.1634/theoncologist.2014-0016.
3. Lindau ST, Abramsohn EM, Matthews AC. A manifesto on the preservation of sexual function in women and girls with cancer. Am J Obstet Gynecol. 2015;213:166–74. 10.1016/j.ajog.2015.03.039.
4. Maclaran K, Panay N. Current concepts in premature ovarian insufficiency. Women's Health (Lond Engl). 2015;11:169–82. 10.2217/whe.14.82.
5. Hickman LC, Valentine LN, Falcone T. Preservation of gonadal function in women undergoin chemotherapy: a review of the potential role for gonadotropin-releasing hormone agonists. Am J Obstet Gynecol. 2016;215(4):415–22.
6. Roness H, Gavish Z, Cohen Y, Meirow D. Ovarian follicle burnout: a universal phenome- non? Cell Cycle. 2013;12:3245–6.
7. Morgan S, Anderson RA, Gourley C, Wallace WH, Spears N. How do chemothera-peutic agents damage the ovary? Hum Reprod Update. 2012;18:525–35.
8. Hasky N, Uri-Belapolsky S, Goldberg K, et al. Gonadotropin-releasing hormone agonists for fertility preservation: unraveling the enigma? Hum Reprod. 2015;30:1089–101.
9. Kim HJ, Yoon TI, Chae HD, Kim JE, Chae EY, Yu JH, et al. Concurrent gonadotropin-releasing hormone agonist administration with chemotherapy improves neoadjuvant chemotherapy responses in young premenopausal breast cancer patients. J Breast Cancer. 2015;18:365–70. 10.4048/jbc.2015.18.4.365.
10. Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS, POEMS/S0230 Investigators Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 2015;372:923–932; doi: https://doi.org/10.1056/NEJMoa1413204.
11. Lambertini M, Del Mastro L, Pescio MC, Andersen CY, Azim HA, Peccatori FA, et al. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med. 2016;14:1–015. 10.1186/s12916-015-0545-7.
12. Practice Committee of American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril. 2013;100:1214–23. 10.1016/j.fertnstert.2013.08.012.
13. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.0.2. The Cochrane Collaboration. In: 2009. http://www.mrc-bsu.cam.ac.uk/cochrane/handbook. Accessed August 2015.
14. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097; doi: https://doi.org/10.1371/journal.pmed.1000097.
15. Bedaiwy MA, Abou-Setta AM, Desai N, Hurd W, Starks D, El-Nashar SA, et al. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. Fertil Steril. 2011;95:906–14.e1. 10.1016/j.fertnstert.2010.11.017.
16. Waxman JH, Ahmed R, Smith D, Wrigley PF, Gregory W, Shalet S, Crowther D, Rees LH, Besser GM, Malpas JS Failure to preserve fertility in patients with Hodgkin’s disease. Cancer Chemother Pharmacol 1987;19:159–162.
17. Gilani MM, Hasanzadeh M, Ghaemmaghami F, Ramazanzadeh F. Ovarian preservation with gonadotropin-releasing hormone analog during chemotherapy. Asia-Pacific Journal of Clinical Oncology. 2007;3:79–83. 10.1111/j.1743-7563.2007.00089.x
18. Giuseppe L, Attilio G, Edoardo DN, Loredana G, Cristina L, Vincenzo L. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology. 2007;12:141–7.
19. Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril. 2009;91:694–7. 10.1016/j.fertnstert.2007.12.044.
20. Sverrisdottir A, Nystedt M, Johansson H, Fornander T. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat. 2009;117:561–7. 10.1007/s10549-009-0313-5.
21. Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol. 2011;29:2334–41. 10.1200/JCO.2010.32.5704.
22. Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA. 2011;306:269–76. 10.1001/jama.2011.991.
23. Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol. 2012;30:533–8. 10.1200/JCO.2011.34.6890.
24. El Gindy EA, El-Haieg DO, Khorshid OM, Ismail EI, Abdelgawad M, Sallam HN, et al. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol. 2013;121:78–86. 10.1097/AOG.0b013e31827374e2.
25. Song G, Gao H, Yuan Z. Effect of leuprolide acetate on ovarian function after cyclophosphamide-doxorubicin-based chemotherapy in premenopausal patients with breast cancer: results from a phase II randomized trial. Med Oncol. 2013;30:667–013. 10.1007/s12032-013-0667-8.
26. Demeestere I, Brice P, Peccatori FA, Kentos A, Dupuis J, Zachee P, et al. No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long-term report of a prospective randomized trial. J Clin Oncol. 2016.
27. Randolph JF, Crawford S, Dennerstein L, Cain K, Harlow SD, Little R, et al. The value of follicle-stimulating hormone concentration and clinical findings as markers of the late menopausal transition. J Clin Endocrinol Metab. 2006;91:3034–40.
28. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.0.2. The Cochrane Collaboration 2009:2015.
29. Light RJ, Pillemer DB. Summing up. The science of reviewing research. Cambridge: Harvard University Press; 1984.
30. Elgindy E, Sibai H, Abdelghani A, Mostafa M. Protecting ovaries during chemotherapy through gonad suppression: a systematic review and meta-analysis. Obstet Gynecol. 2015;126:187–95. 10.1097/AOG.0000000000000905.
31. Oktay K, Sonmezer M. Questioning GnRH analogs for gonadal protection in cancer patients. Fertil Steril. 2009;92:e32. author reply e34
32. Peccatori F, Demeestere I. GnRH analogue for chemotherapy-induced ovarian damage: too early to say? Fertil Steril. 2009;92:e33. author reply e34
33. Leonard RCF, Adamson DJA, Bertelli G, Mansi J, Yellowlees A, Dunlop J, Thomas GA, Coleman RE, Anderson RA. GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial. Ann Oncol. 2017;28:1811–1816.
34. Vitek WS, Shayne M, Hoeger K, Han Y, Messing S, Fung C. Gonadotropin-releasing hormone agonists for the preservation of ovarian function among women with breast cancer who did not use tamoxifen after chemotherapy: a systematic review and meta-analysis. Fertil Steril. 2014;102:808–815.e1.
35. Ben-Aharon I, Gafter-Gvili A, Leibovici L, Stemmer SM. Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-analysis. Breast Cancer Res Treat. 2010;122:803–11.
36. Chen H, Li J, Cui T, Hu L. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev. 2011a:(11):CD008018.
37. Clowse ME, Behera MA, Anders CK, Copland S, Coffman CJ, Leppert PC, et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Women's Health (Larchmt). 2009;18:311–9.
38. Del Mastro L, Ceppi M, Poggio F, Bighin C, Peccatori F, Demeestere I, et al. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. Cancer Treat Rev. 2014;40:675–83.
39. Kim SS, Lee JR, Jee BC, Suh CS, Kim SH, Ting A, et al. Use of hormonal protection for chemotherapy-induced gonadotoxicity. Clin Obstet Gynecol. 2010;53:740–52.
40. Lambertini M, Ceppi M, Poggio F, Peccatori FA, Azim HA Jr, Ugolini D, et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol. 2015;26:2408–19.
41. Munhoz RR, Pereira AA, Sasse AD, Hoff PM, Traina TA, Hudis CA, et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2:65–73.
42. Silva C, Caramelo O, Almeida-Santos T, Ribeiro Rama AC. Factors associated with ovarian function recovery after chemotherapy for breast cancer: a systematic review and meta-analysis. Hum Reprod. 2016;31:2737–49.
43. Sun X, Dongol S, Jiang J, Kong B. Protection of ovarian function by GnRH agonists during chemotherapy: a meta-analysis. Int J Oncol. 2014;44:1335–40.
44. Yang B, Shi W, Yang J, Liu H, Zhao H, Li X, et al. Concurrent treatment with gonadotropin-releasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a meta-analysis of randomized controlled trials. Breast. 2013;22:150–7.
45. Zhang Y, Xiao Z, Wang Y, Luo S, Li X, Li S. Gonadotropin-releasing hormone for preservation of ovarian function during chemotherapy in lymphoma patients of reproductive age: a summary based on 434 patients. PLoS One. 2013;8:e80444.
46. Wang C, Chen M, Fu F, Huang M. Gonadotropin-releasing hormone analog cotreatment for the preservation of ovarian function during gonadotoxic chemotherapy for breast cancer: a meta-analysis. PLoS One. 2013;8:e66360.
47. Lambertini M, Falcone T, Unger JM, Phillips KA, Del Mastro L, Moore HC. Debated role of ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in women with cancer. J Clin Oncol. 2017;35:804–5.
48. Blumenfeld Z, Katz G, Evron A. ‘An ounce of prevention is worth a pound of cure’: the case for and against GnRH-agonist for fertility preservation. Ann Oncol. 2014;25:1719–28.
49. Janse F, Donnez J, Anckaert E, de Jong FH, Fauser BC, Dolmans MM. Limited value of ovarian function markers following orthotopic transplantation of ovarian tissue after gonadotoxic treatment. J Clin Endocrinol Metab. 2011;96:1136–44.
50. Hamy AS, Porcher R, Eskenazi S, Cuvier C, Giacchetti S, Coussy F, et al. Anti-Mullerian hormone in breast cancer patients treated with chemotherapy: a retrospective evaluation of subsequent pregnancies. Reprod BioMed Online. 2016;32:299–307.
51. Steiner A, Pritrchard D, Stancyzk F. Association between biomarkers of ovarian reserve and infertility among older women of reproductive age. JAMA. 2017;318(14):1367–76.